Expected Trial Completion of SAR442257 Study in RRMM and RR-NHL
Mar 17, 2026, 4:00:00 AM UTC
Summary
Sanofi is conducting a Phase 1 first-in-human clinical trial of SAR442257 in patients with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory non-Hodgkin lymphoma (RR-NHL). The study, which began in July 2020 and is no longer recruiting, is expected to complete on March 17, 2026. SAR442257 is an investigational therapy targeting hematologic malignancies. The trial aims to assess safety, pharmacokinetics, and preliminary efficacy in a cohort of 47 participants.
Company
SANOFI (SNY)NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.sanofi.comSimilar Events
Clinical Trial Completion for Isatuximab in RRMM
Sanofi is conducting a multinational, non-interventional observational study of Isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM). The trial, with an enrollment of 586 participants, is expected to complete on February 23, 2026. Isatuximab is a monoclonal antibody targeting CD38, used in the treatment of multiple myeloma. The study aims to gather real-world data on the drug's use and outcomes in RRMM patients.
trial completionPhase 2 Study Completion of SAR444656 in Atopic Dermatitis
The Phase 2 clinical trial of SAR444656, sponsored by Sanofi, is expected to complete on August 18, 2026. The multinational, double-blind, placebo-controlled study is evaluating SAR444656 in adults with moderate to severe atopic dermatitis who are inadequately controlled with topical therapies or are candidates for systemic therapy. The trial aims to assess the safety and efficacy of multiple doses of SAR444656 versus placebo, with an enrollment target of 200 participants. SAR444656 is an investigational therapy for atopic dermatitis, a chronic inflammatory skin condition.
trial completionPhase 2 Clinical Trial Completion for SAR444656 in Hidradenitis Suppurativa
Sanofi is conducting a Phase 2, three-arm clinical trial evaluating SAR444656 in adults with moderate to severe Hidradenitis Suppurativa. The study, which began in September 2023, is expected to complete on July 17, 2026. SAR444656 is an investigational therapy targeting inflammatory pathways in this chronic skin condition. The trial will assess efficacy, safety, pharmacokinetics, and biological effects compared to placebo, with an enrollment target of 156 participants.
trial completionClinical Trial Completion for SAR441566
The clinical trial investigating SAR441566 for ulcerative colitis is expected to complete on May 11, 2028. This Phase 2 study aims to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis, assessing various doses for clinical remission. The trial includes a 52-week treatment period and a follow-up phase, with a total enrollment of 204 participants.
trial completion